TriangleNCT04099251 · OUTCOME
Number of Participants Experiencing Select Adverse Events
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
What was measured
The number of participants experiencing all-cause select adverse events (AEs). An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
Analysis population: All treated participants
Groups in this outcome
Nivolumab
Participants received 480 mg IV Nivolumab in an approximately 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, withdrawal of consent, completion of 12 months of treatment (from first dose of study treatment), disease recurrence, or the study ends, whichever occurred first. Participants began study treatment (Cycle 1) within 3 calendar days of randomization. Subsequent cycles were initiated within ± 3 days of the target visit date.
Placebo
Nivolumab matched placebo (0.9% Sodium Chloride for Injection/5% Dextrose for Injection) IV in a 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, withdrawal of consent, completion of 12 months of treatment (from first dose of study treatment), disease recurrence, or the study ends, whichever occurred first. In the event of disease recurrence, participants on the blinded nivolumab or placebo portion will be offered the option to receive open-label on-protocol nivolumab treatment. Participants received 480 mg IV Nivolumab in a 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, recurrence/progression, withdrawal of consent, completion of 12 months of treatment from first dose of open-label study treatment, whichever occurred first.
| Group | Source count |
|---|---|
| Nivolumab | 524 |
| Placebo | 264 |
Reported measurements
Endocrine
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab | 116 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 14 | Not reported | Not reported | Not reported | Not reported |
Gastrointestinal
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab | 122 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 41 | Not reported | Not reported | Not reported | Not reported |
Hepatic
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab | 86 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 35 | Not reported | Not reported | Not reported | Not reported |
Pulmonary
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab | 10 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 1 | Not reported | Not reported | Not reported | Not reported |
Renal
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab | 30 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 10 | Not reported | Not reported | Not reported | Not reported |
Skin
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab | 217 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 64 | Not reported | Not reported | Not reported | Not reported |
Hypersensitivity/Infusion Reactions
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab | 33 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 2 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 116
- group Id
- OG001
- value
- 14
- title
- Endocrine
- categories
- measurements
- group Id
- OG000
- value
- 122
- group Id
- OG001
- value
- 41
- title
- Gastrointestinal
- categories
- measurements
- group Id
- OG000
- value
- 86
- group Id
- OG001
- value
- 35
- title
- Hepatic
- categories
- measurements
- group Id
- OG000
- value
- 10
- group Id
- OG001
- value
- 1
- title
- Pulmonary
- categories
- measurements
- group Id
- OG000
- value
- 30
- group Id
- OG001
- value
- 10
- title
- Renal
- categories
- measurements
- group Id
- OG000
- value
- 217
- group Id
- OG001
- value
- 64
- title
- Skin
- categories
- measurements
- group Id
- OG000
- value
- 33
- group Id
- OG001
- value
- 2
- title
- Hypersensitivity/Infusion Reactions
- denoms
- counts
- group Id
- OG000
- value
- 524
- group Id
- OG001
- value
- 264
- units
- Participants
- description
- The number of participants experiencing all-cause select adverse events (AEs). An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
- groups
- description
- Participants received 480 mg IV Nivolumab in an approximately 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, withdrawal of consent, completion of 12 months of treatment (from first dose of study treatment), disease recurrence, or the study ends, whichever occurred first. Participants began study treatment (Cycle 1) within 3 calendar days of randomization. Subsequent cycles were initiated within ± 3 days of the target visit date.
- id
- OG000
- title
- Nivolumab
- description
- Nivolumab matched placebo (0.9% Sodium Chloride for Injection/5% Dextrose for Injection) IV in a 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, withdrawal of consent, completion of 12 months of treatment (from first dose of study treatment), disease recurrence, or the study ends, whichever occurred first. In the event of disease recurrence, participants on the blinded nivolumab or placebo portion will be offered the option to receive open-label on-protocol nivolumab treatment. Participants received 480 mg IV Nivolumab in a 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, recurrence/progression, withdrawal of consent, completion of 12 months of treatment from first dose of open-label study treatment, whichever occurred first.
- id
- OG001
- title
- Placebo
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- All treated participants
- reporting Status
- POSTED
- time Frame
- From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
- title
- Number of Participants Experiencing Select Adverse Events
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice